Literature DB >> 24769253

Drug discovery in pulmonary arterial hypertension: attacking the enigmatic root of a deadly weed.

R James White1, Katie L Lannan2, Richard P Phipps3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24769253      PMCID： PMC4386059          DOI： 10.1016/j.drudis.2014.04.008

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


× No keyword cloud information.
  10 in total

1.  Imatinib for the treatment of pulmonary arterial hypertension.

Authors:  Hossein A Ghofrani; Werner Seeger; Friedrich Grimminger
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

Review 2.  One hundred years of research in the pathogenesis of pulmonary hypertension.

Authors:  Ari Zaiman; Iwona Fijalkowska; Paul M Hassoun; Rubin M Tuder
Journal:  Am J Respir Cell Mol Biol       Date:  2005-11       Impact factor: 6.914

3.  Primary pulmonary hypertension. I. Clinical and hemodynamic study.

Authors:  D T DRESDALE; M SCHULTZ; R J MICHTOM
Journal:  Am J Med       Date:  1951-12       Impact factor: 4.965

4.  Reversal of experimental pulmonary hypertension by PDGF inhibition.

Authors:  Ralph Theo Schermuly; Eva Dony; Hossein Ardeschir Ghofrani; Soni Pullamsetti; Rajkumar Savai; Markus Roth; Akylbek Sydykov; Ying Ju Lai; Norbert Weissmann; Werner Seeger; Friedrich Grimminger
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

5.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

Authors:  Z Deng; J H Morse; S L Slager; N Cuervo; K J Moore; G Venetos; S Kalachikov; E Cayanis; S G Fischer; R J Barst; S E Hodge; J A Knowles
Journal:  Am J Hum Genet       Date:  2000-07-20       Impact factor: 11.025

6.  Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.

Authors:  K B Lane; R D Machado; M W Pauciulo; J R Thomson; J A Phillips; J E Loyd; W C Nichols; R C Trembath
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

7.  Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.

Authors:  M Humbert; O Sitbon; A Yaïci; D Montani; D S O'Callaghan; X Jaïs; F Parent; L Savale; D Natali; S Günther; A Chaouat; F Chabot; J-F Cordier; G Habib; V Gressin; Z-C Jing; R Souza; G Simonneau
Journal:  Eur Respir J       Date:  2010-06-18       Impact factor: 16.671

8.  Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.

Authors:  L J Rubin; B M Groves; J T Reeves; M Frosolono; F Handel; A E Cato
Journal:  Circulation       Date:  1982-08       Impact factor: 29.690

Review 9.  Pharmacodynamic profile of prostacyclin.

Authors:  J R Vane; R M Botting
Journal:  Am J Cardiol       Date:  1995-01-19       Impact factor: 2.778

10.  Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

Authors:  Marius M Hoeper; Robyn J Barst; Robert C Bourge; Jeremy Feldman; Adaani E Frost; Nazzareno Galié; Miguel Angel Gómez-Sánchez; Friedrich Grimminger; Ekkehard Grünig; Paul M Hassoun; Nicholas W Morrell; Andrew J Peacock; Toru Satoh; Gérald Simonneau; Victor F Tapson; Fernando Torres; David Lawrence; Deborah A Quinn; Hossein-Ardeschir Ghofrani
Journal:  Circulation       Date:  2013-02-12       Impact factor: 29.690
  10 in total
  2 in total

1.  Features associated with pulmonary arterial hypertension in Chinese hospitalized systemic lupus erythematosus patients.

Authors:  Shu-Zhen Xu; Xiang-Pei Li; Xiao-Mei Li; Zong-Wen Shuai; Rui-Xue Leng; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2018-03-08       Impact factor: 2.980

2.  Low dose monocrotaline causes a selective pulmonary vascular lesion in male and female pneumonectomized rats.

Authors:  Daniel J Lachant; David F Meoli; Deborah Haight; Jason A Lyons; Robert F Swarthout; R James White
Journal:  Exp Lung Res       Date:  2018-01-30       Impact factor: 2.459
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.